1. NCHU Institution Repository
  2. 獸醫學院
  3. 獸醫學系所
Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/93044
標題: Expression of MAGE-A in canine testicular, oral and round cell tumors
MAGE-A 蛋白在犬睪丸腫瘤、口腔腫瘤及圓形細胞腫瘤之表現
作者: Yi-Sheng Chang
張義聖
關鍵字: 無;No
引用: Aprelikova, O., Pandolfi, S., Tackett, S., Ferreira, M., Salnikow, K., Ward, Y., Risinger,J.I., Barrett, J.C., Niederhuber, J., 2009. Melanoma antigen-11 inhibits thehypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.Cancer Research 69, 616-624. Aubry, F., Satie, A.P., Rioux-Leclercq, N., Rajpert-De Meyts, E., Spagnoli,G.C., Chomez, P., De Backer, O., Jégou, B., Samson, M., 2001. MAGE-A4, agerm cell specific marker, is expressed differentially in testicular tumors. Cancer92, 2778-2785. Bai, S., He, B., Wilson, E.M., 2005. Melanoma antigen gene protein MAGE-11regulates androgen receptor function by modulating the interdomain interaction.Molecular and Cellular Biology 25, 1238-1257. Barker, P.A., Salehi, A., 2002. The MAGE proteins: emerging roles in cell cycleprogression, apoptosis, and neurogenetic disease. Journal of NeuroscienceResearch 67, 705-712. Bergeron, A., Picard, V., LaRue, H., Harel, F., Hovington, H., Lacombe, L., Fradet, Y.,2009. High frequency of MAGE-A4 and MAGE-A9 expression in high-riskbladder cancer. International Journal of Cancer 125, 1365-1371. Brasseur, F., Rimoldi, D., Liénard, D., Lethé, B., Carrel, S., Arienti, F., Suter,L., Vanwijck, R., Bourlond, A., Humblet, Y., Vacca,A., Conese,M., Lahaye,T., Degiovanni, G., Deraemaecker, R., Beauduin, M., Sastre, X., Salamon,E., Dréno, B., Jäger, E., Knuth, A., Chevreau, C., Suciu, S., Lachapelle,J., Pouillart, P., Parmiani, G., Lejeune, F., Cerottini, J., Boon, T., Marchand, M 1995. Expression of MAGE genes in primary and metastatic cutaneous melanoma.International Journal of Cancer 63, 375-380. Carrel, S., Schreyer, M., Spagnoli, G., Cerottini, J.C., Rimoldi, D., 1996. Monoclonalantibodies against recombinant-MAGE-1 protein identify a cross-reacting 72-kDaantigen which is co-expressed with MAGE-1 protein in melanoma cells.International Journal of Cancer 67, 417-422. Chambost, H., Van Baren, N., Brasseur, F., Godelaine, D., Xerri, L., Landi, S.J., Theate,I., Plumas, J., Spagnoli, G.C., Michel, G., Coulie, P.G., Olive, D., 2000.Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood 95, 3530-2253. Chang, P.Y., 2013. Expression of MAGE-A protein in canine malignant mammarytumors. Thesis, Department of Veterinary Medicine, College of VeterinaryMedicine, National Chung Hsing University.Chen, Y.C., Hsu, W.L., Chiu, C.Y., Liao, J.W., Chang, C.C., Chang, S.C., 2013.Expression of MAGE--A restricted to testis and ovary or to various cancers indogs. Veterinary Immunology and Immunopathology 153, 26-34. Chen, Y.T., Stockert, E., Chen, Y., Garin-Chesa, P., Rettig, W.J., van der Bruggen,P., Boon, T., Old, L.J., 1994. Identification of the MAGE-1 gene product bymonoclonal and polyclonal antibodies. Proceedings of the National Academy ofSciences of the United States of America 91, 1004-1008. Cheng, Y.H., Wong, E.W., Cheng, C.Y., 2011. Cancer/testis (CT) antigens,carcinogenesis and spermatogenesis. Spermatogenesis 1,209-220. Cheville, J.C., Roche, P.C., 1999. MAGE-1 and MAGE-3 tumor rejection antigens inhuman germ cell tumors. Modern Pathology 12, 974-978. Chomez, P., De Backer, O., Bertrand, M., De Plaen, E., Boon, T., Lucas, S., 2001. Anoverview of the MAGE gene family with the identification of all human members of the family. Cancer Research 61, 5544-5551. Dabovic, B., Zanaria, E., Bardoni, B., Lisa, A., Bordignon, C., Russo, V., Matessi, C.,Traversari, C., Camerino, G., 1995. A family of rapidly evolving genes from thesex reversal critical region in Xp21. Mammalian Genome 6, 571-580. De Plaen, A., K., Traversari, C., Gaforio, J.J., Szikora, J.P., De Smet, C., Brasseur, F.,van der Bruggen, P., Lethé, B., Lurquin, C., Brasseur, R., Chomez, P., De Backer,O., Cavenee, W., Boon, T., 1994.Structure, chromosomal localization, andexpression of 12 genes of the MAGE family. Immunogenetics 40, 360-369. De Smet, C., Lurquin, C., Lethé, B., Martelange, V., Boon, T., DNA methylation is theprimary silencing mechanism for a set of germ line- and tumor-specific genes witha CpG-rich promoter. Molecular and Cellular Biology 19, 7327-7335. Feng, Y.C., 2012. Generation of a polyclonal mouse anti-canine MAGE-A antibody.Thesis, Department of Veterinary Medicine, College of Veterinary Medicine,National Chung Hsing University.Gibbs, P., Hutchins, A.M., Dorian, K.T., Vaughan, H.A., Davis, I.D., Silvapulle,M., Cebon, J.S., 2000. MAGE-12 and MAGE-A are frequently expressed inmalignant melanoma. Melanoma research 10, 259-264. Hara, I., Hara, S., Miyake, H., Yamanaka, K., Nagai, H., Gohji, K., Arakawa,S., Kamidono, S.. 1999. Expression of MAGE genes in testicular germ cell tumors.Urology 53, 843-847. Haurum, J.S., 2006. Recombinant polyclonal antibodies: the next generation of antibodytherapeutics? Drug Discovery Today 11, 655-660. Hayes, H.M. Jr., Pendergrass, T.W., 1976. Canine testicular tumors: epidemiologicfeatures of 410 dogs. International Journal of cancer 15. 482-497. Hofbauer, G.F., Schaefer, C., Noppen, C., Böni, R., Kamarashev, J., Nestle, F.O., Spagnoli, G.C., Dummer, R., 1997. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency anddistribution. The American Journal of Pathology 151, 1549-1553. Huang, L.Q.1, Brasseur, F., Serrano, A., De Plaen, E., van der Bruggen, P., Boon,T., Van Pel, A., 1999. Cytolytic T lymphocytes recognize an antigen encode byMAGE-A10 on a human melanoma. Journal of immunology 162, 6849-6854. Janitz, M., Fiszer, D., Michalczak-Janitz, K., Lukaszyk, A., Fernandez, N., Skorupski,W., Kurpisz, M., 1994. Analysis of mRNA for class I HLA on human gametogeniccells. Molecular Reproduction and Development 38, 231-237. Jungbluth, A.A., Busam, K.J., Kolb, D., Iversen, K., Coplan, K., Chen, Y.T., Spangoli,G.C., Old, L.J., 2000. Expression of MAGE-antigens in normal tissues and cancer.International Journal of Cancer 85, 460-465. Jungbluth, A.A., Silva Jr., Iversen, K., Frosina, D., Zaidi, B., Coplan, K., Eastlake-Wade, S.K., Castelli, S.B., Spagnoli, G.C., Old, L.J., Vogel, M., 2007. Expressionof cancer-testis (CT) antigens in placenta. Cancer Immunity 7, 15.Jurk, M., Kremmer, E., Schwarz, U., Förster, R., Winnacker, E.L., 1998. MAGE-11protein is highly conserved in higher organisms and located predominantly in thenucleus. International Journal of Cancer 75, 762-766. Karpf, A.R., Bai, S., James, S.R., Mohler, J.L., Wilson, E.M., 2009. Increasedexpression of androgen receptor coregulator MAGE-11 in prostate cancer by DNAhypomethylation and cyclic AMP. Molecular cancer Research 7, 523-535. Kendall, S.E., Goldhawk, D.E., Kubu, C., Barker, P.A., Verdi, J.M., 2002.Expression analysis of a novel p75(NTR) signaling protein,which regulates cell cycleprogression and apoptosis. Mechanisms of Development117, 187-200. Kocher, T., Schultz-Thater, E., Gudat, F., Schaefer, C., Casorati, G., Juretic,A., Willimann, T., Harder, F., Heberer, M., Spagnoli, G.C., 1995. Identificationand intracellular location of MAGE-3 gene product. Cancer Research 55, 2236-2239. Kocher, T., Zheng, M., Bolli, M., Simon, R., Forster, T., Schultz-Thater, E., Remmel,E., Noppen, C., Schmid, U., Ackermann, D., Mihatsch, M.J., Gasser, T.,Heberer,M., Sauter, G., Spagnoli, G.C., 2002. Prognostic relevance of MAGE-A4 tumorantigen expression in transitional cell carcinoma of the urinary bladder: a tissuemicroarray study. International Journal of Cancer 100, 702-705. Laduron, S., Deplus, R., Zhou, S., Kholmanskikh, O., Godelaine, D., De Smet,C., Hayward, S.D., Fuks, F., Boon, T., De Plaen, E., 2004. MAGE-A1 interactswith adaptor SKIP and the deacetylase HDAC1 to repress transcription. NucleicAcid Research 32, 4340-4350. Landry, C., Brasseur, F., Spagnoli, G.C., Marbaix, E., Boon, T., Coulie, P., Godelaine,D., 2000. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. International Journal of Cancer 86, 835-841. Lian, Y., Sang, M., Ding, C., Zhou, X., Fan, X., Xu, Y., Lü, W., Shan, B., 2012.Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognosticsignificance: a retrospective clinical study. Journal of Cancer Research andClinical Oncology 138, 519-527. Lipman, N.S., Jackson, L.R., Trudel, L.J., Weis-Garcia, F., 2005. Monoclonal versuspolyclonal antibodies: distinguishing characteristics, applications, and informationresources. ILAR journal 46, 258-268. Liu, W., Cheng, S., Asa, S.L., Ezzat, S., 2008. The melanoma-associated antigen A3mediates fibronectin-controlled cancer progression and metastasis. Cancer Research 68, 8104-8112. Lucas, S., Brasseur, F., Boon, T., 1999. A new MAGE gene with ubiquitous expressiondoes not code for known MAGE antigens recognized by T cells. Cancer Research59, 4100-4103. Lucas, S., De Plaen, E., Boon, T., 2000. MAGE-B5, MAGE-B6, MAGE-C2 andMAGE-C3: four new members of the MAGE family with tumor-specificexpression. International Journal of Cancer 87, 55-60. Lucas, S., De Smet, C., Arden, K. C., Viars, C. S., Lethe´, B., Lurquin, C., Boon, T.,1998. Identification of a new MAGE gene with tumor-specific expression byrepresentational difference analysis. Cancer Research 58, 743-752. Lurquin, C., De Smet, C., Brasseur, F., Muscatelli, F., Martelange, V., De Plaen, E.,Brasseur, R., Monaco, A. P., Boon, T., 1997. Two members of the human MAGEBgenefamily located in Xp.21.3 are expressed in tumors of various histologicalorigins. Genomics 46, 397-408. Ma, Z., Khatlani, T.S., Ohno, K., Sasaki, K., Inokuma, H., Onishi, T., 2000. Cloningand sequencing of canine MAGE cDNA. Tissue Antigens 56, 166-169. Macy, D.W., MacEwen, E.G., 2007. Diagnostic cytology in clinical oncology. In:Withrow, S.J., Vail, D.M., editors. Small animal clinical oncology, forth ed.Missouri: Saunders Elsevier Co. pp. 122-133. Marcar, L., Maclaine, N.J., Hupp, T.R., Meek, D.W., 2010. Mage-A cancer/testisantigens inhibit p53 function by blocking its interaction with chromatin. CancerResearch 70, 10362-10370. Meek, D.W., Marcar, L., 2012. MAGE-A antigens as targets in tumour therapy. CancerLetters 324, 126-132. Monte, M., Simonatto, M., Peche, L.Y., Bublik, D.R., Gobessi, S., Pierotti, M.A., Rodolfo, M., Schneider, C., 2006. MAGE-A tumor antigens target p53transactivation function through histone deacetylase recruitment and conferresistance to chemotherapeutic agents. Proceedings of the National Academy ofSciences 103, 11160-11165. Muscatelli, F., Walker, A.P., De Plaen, E., Stafford, A.N., Monaco, A.P., 1995.Isolation and characterization of a new MAGE gene family in the Xp21.3 region.Proceedings of the National Academy of Sciences of the United States of America92, 4987-4991. Nagao, T., Higashitsuji, H., Nonoguchi, K., Sakurai,T., Dawson, S., Mayer, R.J., 2003.MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses itstumorigenic activity. The Journal of Biological Chemistry 278, 10668–10674. Nardiello, T., Jungbluth, A.A., Mei, A., Diliberto, M., Huang, X., Dabrowski,A., Andrade, V.C., Wasserstrum, R., Ely, S., Niesvizky, R., Pearse, R., Coleman,M.,Jayabalan, D.S., Bhardwaj, N., Old, L.J., Chen-Kiang, S, Cho H.J., 2011.MAGE-A inhibits apoptosis in proliferating myeloma cells through repression ofBax and maintenance of survivin. Clinical Cancer Research 17, 4309-42019. Nelson, P.T., Zhang, P.J., Spagnoli, G.C., Tomaszewski, J.E., Pasha, T.L., Frosina,D., Caballero, O.L., Simpson, A.J., Old, L.J., Jungbluth, A.A., 2007. Cancer/testis(CT) antigens are expressed in fetal ovary. Cancer Immunity 7, 1.Ohman, F. K., Nordqvist, K., 2001. The melanoma antigen genes-any clues to theirfunctions in normal tissues. Experimental Cell Research 265, 185-194. Olarte, I., Martinez, A., Ramos-Peñafiel, C., Castellanos-Sinco, H., Zamora, J., Collazo-Jaloma, J., Gutiérrez, M., Gutiérrez-Kobeh, L., Chavez-Olmos, P., Manzanilla, H.,Garrido-Guerrero, E., Ordoñez-Razo, R.M., Miranda, E.I., 2011. MAGE-A3expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Hematology 16, 368-372. Owen, L.N., 1980. TNM Classification of tumours in Domestic Animals, First Ed.Geneva, Switzerland: World Health Organization.Peikert, T., Specks, U., Farver, C., Erzurum, S.C., Comhair, S.A., 2006. Melanomaantigen A4 is expressed in non-small cell lung cancers and promotes apoptosis.Cancer Research 66, 4693-4700. Picard, V., Bergeron, A., Larue, H., Fradet, Y., 2007. MAGE-A9 mRNA and proteinexpression in bladder cancer. International Journal of Cancer 120, 2170-2177. Põld, M., Zhou, J., Chen, G.L., Hal,l J.M., Vescio, R.A., Berenson, J.R., 1999.Identification of a new, unorthodox member of the MAGE gene family. Genomics59, 161-167. Ramos-Vara, J.A., Beissenherz, M.E., Miller, M.A., Johnson, G.C., Pace, L.W., Fard,A., Kottler, S.J., 2000. Retrospective study of 338 canine oral melanomas withclinical, histologic, and immunohistochemical review of 129 cases. VeterinaryPathology 37. 597-608. Rimoldi, D., Salvi, S., Schultz-Thater, E., Spagnoli, G.C., Cerottini, J.C., 2000. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to studydifferent proteins of the MAGE-A family. International Journal of Cancer 86, 749-751. Rimoldi, D., Salvi, S., Reed, D., Coulie, P., Jongeneel, V.C., De Plaen, E., Brasseur,F., Rodriguez, A.M., Boon, T., Cerottini, J.C., 1999. cDNA and proteincharacterization of human MAGE-10. International Journal of Cancer 82, 901-907. Rogner, U.C., Wilke, K., Steck, E., Korn, B., Poustka, A., 1995. The melanoma antigengene (MAGE) family is clustered in the chromosomal band Xq28. Genomics 29,725-731. Sakurai, T., Itoh, K., Higashitsuji, H., Nagao, T., Nonoguchi, K., Chiba, T., Fujita, J.,2004. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis inhuman cells. The Journal of Biological Chemistry 279, 15505-15514. Sang, M., Wang, L., Ding, C., Zhou, X., Wang, B., Wang, L., Lian, Y., Shan, B., 2011.Melanoma-associated antigen genes - an update. Cancer Letters 302, 85-90. Simpson, A.J.G., Caballero, O.L., Jungbluth, A., Chen, Y.T., Old, L.J., 2005.Cancer/testis antigens gametogenesis and cancer. Nature Review Cancer 5, 615-625. Takahashi, K., Shichijo, S., Noguchi, M., Hirohata, M., Itoh, K., 1995. Identification ofMAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes oftestis. Cancer Research 55, 3478-3482. Todoroff, R.J., Brodey, R.S., 1979. Oral and pharyngeal neoplasia in the dog: aretrospective survey of 361 cases. Journal of American veterinary MedicalAssociation 175, 567-571. Tsai, H.Y., 2010. Association between clinicopathologic characteristics and KITexpression or c-kit mutation in canine mast cell tumors. Thesis, Department ofVeterinary Medicine, College of Veterinary Medicine, National Chung HsingUniversity.van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van denEynde, B., Knuth, A., Boon, T., 1991. A gene encoding an antigen recognized bycytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647. Weeraratne, S.D., Amani, V., Neiss, A., Teider, N., Scott, D.K., Pomeroy, S.L., Cho,Y.J., 2011. miR-34a confers chemosensitivity through modulation of MAGE-Aand p53 in medulloblastoma. Neuro-Oncology 13, 165-175. Wischnewski, F., Pantel, K., Schwarzenbach, H., 2006. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 inhuman cancer cells. Molecular cancer research 4, 339-349. Yang, B., O'Herrin, S.M., Wu, J., Reagan-Shaw, S., Ma, Y., Bhat, K.M., Gravekamp,C., Setaluri, V., Peters, N., Hoffmann, F.M., Peng, H., Ivanov, A.V., Simpson,A.J., Longley, B.J., 2007. MAGE-A, mMage-b, and MAGE-C proteins formcomplexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positivecell lines. Cancer Research 67, 9954–9962. Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, MorikawaT, Kondo S, Ikeda H, Nishimura T., 2006. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lungcarcinoma and their prognostic significance. International Journal of Oncology 28,1089-1098. Zhao, Q., Caballero, O.L., Simpson, A.J., Strausberg, R.L., 2012. Differential evolutionof MAGE genes based on expression pattern and selection pressure. PLoS One 7, e48240.
摘要: 
黑色素瘤相關抗原-A (melanoma associated antigen-A, MAGE-A)是癌症/睪丸抗原(cancer/testis antigen)的一種。這些抗原只會表現在正常的原始生殖細胞及多種腫瘤細胞中。人類的 MAGE-A 基因共有 12 種亞型，分別為 MAGE-A1 到MAGE-A12。所有的 MAGE-A 都有一段高度相似的氨基酸序列，其大小約為 200個氨基酸。本研究室先前已經製備出鼠抗犬 18-kDa MAGE-A 片段之多株抗體，並且以免疫組織化學染色法來偵測犬正常組織中 18-kDa MAGE-A 的表現。在所有受測的正常組織中只有睪丸中的原始生殖細胞呈現陽性。本實驗進一步使用此抗體以免疫組織化學染色法偵測犬的睪丸腫瘤，口腔腫瘤以及圓形細胞瘤中 18-kDa MAGE-A 的表現。睪丸腫瘤包括 10 個精母細胞瘤，10 個賽托利細胞瘤及 10個間質細胞瘤；口腔腫瘤包括 17 個黑色素瘤，10 個鱗狀上皮細胞瘤，6 個纖維肉瘤及 12 個齒齦瘤；圓形細胞包括 12 個組織球相關疾病，11 個多中心型淋巴瘤，20 個肥大細胞瘤，10 個漿細胞瘤及 10 個傳染性花柳性腫瘤。結果顯示 18-kDa MAGE-A 在睪丸腫瘤中有 33% (10/30)的陽性率，在口腔腫瘤中有 24%(11/45)的陽性率，而在圓形細胞瘤中則有 33% (21/53)的陽性率。在這些腫瘤中，賽托利細胞瘤、間質細胞瘤、齒齦瘤及傳染性花柳性腫瘤皆無 18-kDa MAGE-A的表現，而精母細胞瘤(100%, 10/10)、淋巴瘤(54.5%, 6/11)及肥大細胞瘤(55%,11/20)則有明顯的陽性表現。經由 Fisher's exact test 的分析，18-kDa MAGE-A 在口腔黑色素瘤、淋巴瘤及肥大細胞瘤中的表現與否在不同的臨床分期或組織學分級之間並無顯著差異。由於 18-kDa MAGE-A 只表現在犬正常的原始生殖細胞與多種腫瘤中，此蛋白或許可做為腫瘤的生物標的蛋白。

Melanoma associated antigen-A (MAGE-A) is one superfamily of the cancer/testis antigens which is only expressed in normal primary germ cells and various types of cancers. There are 12 subtypes of MAGE-A in human, from MAGE-A1 to MAGE-A12. All of MAGE-A share a homology domain consisting of about 200 amino acids. A polyclonal mouse anti-dog 18-kDa MAGE-A antibody was produced in our lab. This antibody was applied to detect 18-kDa MAGE-A in normal canine tissues by immunohistochemical staining. Results revealed that all the tested normal canine tissues were negative except testicular germ cells. The expression of 18-kDa MAGE-A in canine testicular, oral and round cell tumors was further investigated by immunohistochemical staining with the same antibody. Testicular tumors included 10 seminomas, 10 Sertoli cell tumors and 10 Leydig cell tumors. Oral tumors comprised of 17 melanomas, 10 squamous cell carcinomas, 6 fibrosarcomas and 12 epulides. Round cell tumors consisted of 12 histiocytic diseases, 11 multicentric lymphomas, 20 mast cell tumors, 10 plasmacytomas, 10 transmissible venereal tumors. The positive immunolabelling of 18-kDa MAGE-A were 33% (10/30) in testicular tumor, 24% (11/45) in oral tumors and 33% (21/63) in round cell tumors. Among these tumors, negative immunostaining were showed in Sertoli cell tumors, Leydig cell tumors, epulides and transmissible venereal tumors, but significant immunoreactivity was observed in seminomas (100%, 10/10), multicentric lymphomas (54.5%, 6/11) and mast cell tumors (55%, 11/20). There was no statistical difference between the expression of 18-kDa MAGE-A and tumor stages or grades of oral melanoma, multicentric lymphoma and mast cell tumor in Fisher's exact test. Based on its restrictive expression in normal canine germ cells and various types of neoplasm, 18-kDa MAGE-A has the potential to be used as a biomarker for tumors.
URI: http://hdl.handle.net/11455/93044
其他識別: U0005-0605201514512300
Rights: 不同意授權瀏覽/列印電子全文服務
Appears in Collections:獸醫學系所

Files in This Item:
File SizeFormat Existing users please Login
nchu-103-7101038001-1.pdf2.69 MBAdobe PDFThis file is only available in the university internal network   
Show full item record
 
TAIR Related Article

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.